Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of FEXUCLUE 40 mg (fexuprazan hydrochloride) for night reflux symptoms in GERD
KCT0009598Phase 4Terminated
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fexuprazan in erosive esophagitis (EE), gastroesophageal reflux disease (GERD), sponsored by Daewoong Pharmaceutical. Started Dec 2024; status: terminated.
02
Drugs
fexuprazan
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on KCT0009598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009598.